End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 MYR | +0.80% | +1.61% | 0.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 257M | B | ||
+20.76% | 43.77B | B- | ||
+28.00% | 22.83B | B+ | ||
+20.25% | 15.56B | - | ||
+18.82% | 14.34B | B+ | ||
+55.83% | 12.96B | B | ||
-0.05% | 6.79B | - | - | |
-12.70% | 6.41B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.65% | 5.69B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DPHARMA Stock
- Ratings Duopharma Biotech